The Science of Age-less Living

Welcome to The Science of Age-Less Living ! Dr. Ethan Hausman-Marquis—logevity researcher, biohacker and founder of The Catalyst Clinic—shares his journey into the fields of aesthetics, regenerative medicine, and longevity science, and offers a look at what the future of aging may hold. From his early studies at UCLA to advanced work in genomics and molecular biology at L’École Normale Supérieure in Paris and a PhD at the Karolinska Institute in Stockholm, Dr. Ethan’s path has been guided by one goal: helping people live longer, healthier, and more vibrant lives. He is the author of Exploring the World of Peptides: From Basics to Breakthroughs and Peptide-Based Cancer Therapies: A New Frontier in Precision Medicine , and has contributed to several peer-reviewed publications on cutting-edge medical research. In this episode, Dr. Ethan reflects on his transition from academic research to clinical innovation at The Catalyst Clinic—with locations in London, New York, Amsterdam, and soon Zürich—and sets the stage for what’s to come in future episodes. Each week, The Science of Age-Less Living explores the molecular and cell biology of longevity—the evolving landscape of regenerative medicine, the power of peptides, the genetics of aging, and the simple, practical tools that can help you thrive at any age. Join us as we explore what it truly means to age well—combining science, medicine, and mindset to help you live not just longer, but better. Let’s begin the journey to Age-Less Living. Learn more at: thecatalystclinic.com/wellness/peptide-therapy

The Science of Age-less Living is a health podcast hosted by Unknown Host, with 46 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts The Science of Age-less Living, a health show with 46 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #21

  The Age-less Night: How Your Pineal Gland Rewrites Your Genes While You Sleep

  Aug 3, 202621 minS2

  Most people treat sleep as simple recovery, but this episode reframes it as the nightly window in which a gland smaller than a pea helps decide how fast you age. That gland is the pineal gland, buried at the center of your brain, and its job is to release melatonin — not really a "sleep chemical" but a darkness signal that tells every cell in your body it's night. This signal is wired to light hitting your eyes and routed through your brain's master clock, the SCN. The catch: the pineal gland tends to calcify and its melatonin output declines with age, so the darkness signal that once washed cleanly through your body every night grows quieter over the decades. That fading signal matters because you don't have one clock — you have trillions. Nearly every cell runs its own roughly-24-hour rhythm built from "clock genes," and those genes control the timing of a huge share of what your body does, from DNA repair to metabolism to immune activity. Melatonin helps keep all these clocks synchronized. When chronic stress and poor sleep scramble that synchronization, gene expression shifts: the inflammation program (driven by NF-κB) creeps on, while repair-and-protection systems tied to the clock — like the longevity-linked SIRT1 — get thrown off schedule. Crucially, none of this mutates your DNA; it changes which genes are switched on and off through epigenetic "bookmarks" that respond to how you live. The hopeful takeaway is that because these are shifts in gene expression rather than permanent damage, much of it responds to daily behavior. The episode's highest-leverage moves are unglamorous and free: get bright light into your eyes early in the morning, defend real darkness in the hour before bed, keep your sleep timing consistent, and wind down evening stress so your cortisol rhythm stays intact. Melatonin supplements are framed honestly as a timing tool, not a proven anti-aging cure. The through-line is the show's core promise — that the most powerful levers on aging are often the quietest ones you already control.

  ListenShow Notes
• 

  Episode #20

  The Age-Less Off-Ramp: What Happens When You Stop GLP-1s

  Jul 26, 202630 minS2

  The GLP-1 receptor agonists are the most effective weight loss agents ever brought to market, and their efficacy is entirely contingent on continued administration. Three randomized withdrawal studies across two molecules make this unambiguous: the STEP-1 extension found participants regained roughly two-thirds of their lost weight within a year of stopping, with blood pressure, lipids, glycaemia and inflammatory markers reverting alongside it. STEP-4 and SURMOUNT-4 showed the same pattern under cleaner designs, with the gap between continuing and stopping running to fifteen percentage points of body weight in under a year. The science of getting onto these drugs is mature. The science of getting off them is roughly a decade behind. This episode explains why, and the answer is physiological rather than behavioral. Weight loss of any kind provokes a coordinated defense — leptin falls disproportionately, ghrelin rises above pre-treatment levels, satiety peptides decline, and energy expenditure adapts downward — and that response persists for at least a year. Throughout treatment, the drug doesn't resolve this counter-regulation; it masks it by agonizing the same receptors the system uses to signal satiety. Withdraw the drug and what emerges isn't the patient's old appetite. It's the unopposed appetite of a person who has just lost fifteen percent of their body weight. Compounding this is an asymmetry in body composition: lean tissue is lost readily and regained poorly, so a completed cycle returns the patient to their starting weight with a worse ratio — a trajectory that runs directly counter to healthy aging. We work through the pharmacology properly — albumin-binding, hypothalamic melanocortin signaling, dual GIP/GLP-1 agonism, the mesolimbic reward effects — then take the off-ramp strategies one at a time and label the evidence for each honestly: chronic therapy, maintenance dosing, tapering, bridging technologies like Fractyl's duodenal resurfacing, and the next-generation oral and triple agonists. Most of what is currently done in clinical practice rests on mechanistic reasoning rather than trial data, and the distinction matters. The conclusion is straightforward: these drugs are a chronic therapy for a chronic condition, not a course of treatment, and anyone presenting them as a finite intervention with a permanent result is either not reading the withdrawal trials or choosing not to mention them.

  ListenShow Notes
• 

  Episode #18

  Age-less or Overhyped? The Sixty-Year Cerebrolysin Puzzle | The Age-Less Top 20 Peptides

  Jul 17, 202625 minS2

  Episode summary Cerebrolysin is a peptide preparation with a strange résumé: developed in Austria more than sixty years ago, approved in nearly fifty countries for stroke, traumatic brain injury, and dementia, put through hundreds of clinical trials — and yet still surrounded by a genuinely unresolved question about whether it works. In this episode we unpack what it actually is (not a single peptide, but a standardized mixture of amino acids and small fragments made by enzymatically digesting pig brain tissue), the one clever idea at its core (fragments small enough to slip across the blood-brain barrier and mimic the brain's own neurotrophic factors like BDNF and NGF), and the crucial gap between an effect in a lab dish and a real benefit in a human being. Then we get to the part the marketing skips. A 2023 systematic review found Cerebrolysin likely offers no benefit for survival in acute ischemic stroke and may even raise the rate of serious adverse events — and much of the supportive research has been funded by the manufacturer. We also cover the uncomfortable reality behind the vials sold online: it's not FDA-approved in the US, and the "research use only" label is a legal workaround for shipping an unregulated injectable with no purity or sterility guarantees. The takeaway is neither hype nor dismissal — Cerebrolysin is a genuinely interesting compound aimed at a real target, but the honest evidence says it's worth watching, not worth self-experimenting on with a needle. As always: not medical advice, and a real conversation for a licensed physician.

  ListenShow Notes
• 

  Episode #19

  Age-less by Design: Inside the Cell's Peptide Factory

  Jul 14, 202623 minS2

  Episode summary Right now, inside every cell in your body, trillions of microscopic factories are assembling molecules called peptides — the short chains of amino acids your body uses to talk to itself, from insulin to oxytocin. But how does your body actually build one? In this episode we follow a single peptide all the way from blueprint to finished product, using the real scientific terms but giving you a picture for every one. We start in the "library" of your DNA, where each recipe is written in three-letter words called codons, then watch the cell make a disposable photocopy — messenger RNA — so the precious original never has to leave. That copy travels to the ribosome, the cell's assembly line, where a fleet of molecular "delivery trucks" brings exactly the right amino acids and snaps them into a chain, bead by bead. But coming off the assembly line isn't the finish line. We walk through the finishing shop — where the floppy chain folds into its working shape, gets reinforced with molecular "staples," and is often trimmed down from an oversized version (the surprising way your body actually builds insulin) — and then the packaging and shipping department that releases the final peptide out into your body. We close by zooming out to nature's other method of building peptides without a ribosome at all (the route behind many antibiotics), and how humans manufacture peptides ourselves, from building them one bead at a time in the lab to turning engineered bacteria into living insulin factories. By the end, you'll understand one of the most elegant manufacturing processes in the known universe — the one that's been running inside you your whole life.

  ListenShow Notes
• 

  Episode #17

  Age-Less LL-37: The Antibiotic in Your Blood | The Age-Less Top 20 Peptides

  Jul 13, 202632 minS2

  LL-37 is the odd one out in the Age-Less peptide series. Where Humanin and MOTS-c were mitochondrial longevity signals, LL-37 is the human cathelicidin — your body's own broad-spectrum antibiotic, a small positively charged peptide cut from a larger precursor and stationed at every barrier where you meet the outside world. Dr. Ethan walks through what it actually is: how it's encoded, how it's stored and released, and how that little two-faced helix kills bacteria on contact, neutralizes endotoxin, recruits immune cells, heals wounds, and links your innate immunity to your vitamin D status. Then he turns the coin over. LL-37 is genuinely double-edged — a superb defender when it fires correctly, and a documented driver of disease when it doesn't. This episode lays out the mechanisms behind its role in psoriasis, rosacea, and lupus, explains why "more is better" is exactly the wrong instinct here, and separates the strong evidence for your own endogenous LL-37 from the thin, narrow evidence for LL-37 as an administered therapy. Along the way: the real vitamin D connection (and why supplementing on top of sufficiency won't reliably raise it), and why a regulator has specifically flagged this molecule as a safety concern. The honest bottom line runs opposite to the marketing. This isn't a level to chase or a peptide to inject — it's a system to keep in good working order. No hype, no discount codes: just what LL-37 is, what it does, what the human data shows, and what the regulatory picture actually looks like in 2026. One note: I kept the title's framing accurate to the science (the "shouldn't inject" line reflects the real safety picture, not editorializing). If you'd prefer something shorter or more neutral for a feed, say the word and I'll trim it.

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.